Liquid biopsies have emerged as a minimally invasive method to analyze cell-free DNA (cfDNA) fragments shed by tumors into the bloodstream. This approach has revolutionized cancer diagnostics by enabling continuous monitoring of tumor genomics without the need for traditional tissue biopsies. However, one grave challenge persists: the high background noise stemming from mutations accumulated in white blood cells through clonal hematopoiesis. This confounding signal often leads to ambiguity in discerning whether detected mutations truly originate from tumor cells or from aging-related alterations in blood cells, complicating therapeutic choices.

The plasmaCHORD model ingeniously tackles this challenge by scrutinizing distinct fragmentation patterns of cfDNA. Tumor-derived DNA fragments and those from white blood cells undergo differential cleavage processes, resulting in unique cfDNA fragmentation profiles. By leveraging these patterns alongside patient-specific variables such as age, gene involved, and mutation characteristics, the algorithm accurately predicts the source of each mutation. This nuanced analysis goes well beyond traditional sequencing, which often treats detected mutations without contextual origin differentiation.

Training plasmaCHORD involved the comprehensive analysis of liquid biopsy data from 225 patients afflicted with a variety of solid tumors including breast, colorectal, esophageal, ovarian, and non-small cell lung cancers. The model’s predictive power was rigorously validated using matched tumor biopsy and white blood cell sequencing, guaranteeing that the classification of mutation origins was grounded in unequivocal biological evidence. The initial results revealed a marked improvement in correctly identifying tumor mutations, setting a new benchmark for clinical molecular diagnostics.

To test the model’s robustness, the research team applied plasmaCHORD to an independent cohort comprising 114 patients with breast, prostate, or non-small cell lung cancers sourced from a different institution employing a different liquid biopsy sequencing technology. Remarkably, the tool maintained similar accuracy, distinguishing tumor mutations from hematopoietic mutations with high fidelity. PlasmaCHORD boosted the accuracy rates from a near-coin-flip 50% baseline to an impressive 83% for key mutations with clinical significance, underscoring its potential for widespread clinical adoption.

Clinically, this innovation transcends theoretical modeling, as demonstrated through its deployment within the Johns Hopkins Molecular Tumor Board. Integrating plasmaCHORD’s predictions enabled clinicians to circumvent the pitfall of selecting ineffective treatments driven by misattributed mutations. By ensuring that only tumor-specific mutations guide therapeutic decisions, the model optimizes patient outcomes, potentially reducing unnecessary drug exposure and associated toxicities. This synergy of artificial intelligence and clinical oncology epitomizes the future of personalized cancer treatment.

One-third of mutations identified in tumor-naive liquid biopsies are believed to stem from white blood cells — a statistic that has long hindered the clinician’s ability to tailor precision therapies based on liquid biopsy results alone. By incorporating plasmaCHORD into the diagnostic workflow, oncologists gain an unprecedented clarity to confidently target mutations that genuinely underpin the patient’s malignancy, thereby reinforcing the integral link between molecular profiling and precision therapy.

The impetus behind plasmaCHORD is grounded in a deep understanding of cfDNA biology. DNA fragments circulating in the blood originate from multiple physiological processes, each imparting distinct fragmentation signatures. Tumor cells often release DNA with specific sizes and cleavage patterns due to apoptosis and necrosis mechanisms distinct from those active in hematopoietic cells. Capturing these fragmentation nuances enables plasmaCHORD to function as a molecular detective, distinguishing subtle signals in a complex cfDNA milieu.

The Johns Hopkins research team led by co-authors Jenna Canzoniero, M.D., M.S., and Valsamo Anagnostou, M.D., Ph.D., envisions that future iterations of plasmaCHORD will refine predictive accuracy even further. Plans are underway to integrate additional genomic and epigenomic features, as well as to validate the model across larger and more diverse populations. Such advances will pave the way for plasmaCHORD to be seamlessly embedded into routine clinical workflows and multi-institutional cancer genomic databases.

Collaborative efforts across multiple academic and industry institutions, including Vanderbilt University, LabCorp, and the Netherlands Cancer Institute, underscore the broad interest and trust in plasmaCHORD’s transformative potential. Funding from prestigious bodies such as the National Cancer Institute and the Department of Defense reflects the critical importance of this research to national cancer control priorities and the future of cancer care innovation.

The advent of plasmaCHORD exemplifies how artificial intelligence can unravel complex biological signals obscured by noise, delivering enhanced diagnostic precision. As liquid biopsies continue to gain prominence, tools like plasmaCHORD will be instrumental not only in honing treatment selection for individual patients but also in accelerating research toward overcoming cancer’s evolving genetic landscape.

In summary, plasmaCHORD stands as a beacon of progress in the quest to decode the biological origin of cfDNA mutations. By marrying novel machine learning algorithms with deep molecular understanding, it elevates liquid biopsy from a promising concept to a powerful clinical utility, allowing oncologists to focus precisely on the genetic hallmarks of tumors and tailor therapies with newfound confidence and accuracy.

Subject of Research: Application of machine learning to improve mutation source identification in liquid biopsies for cancer diagnosis and treatment.

Article Title: Development of an artificial intelligence method to accurately characterize mutations in liquid biopsies

News Publication Date: May 1, 2024

Web References:
https://doi.org/10.1158/1078-0432.CCR-25-0976
https://www.hopkinsmedicine.org/kimmel-cancer-center

Image Credits: Valsamo Anagnostou/ChatGPT

Keywords: Liquid biopsy, cell-free DNA, plasmaCHORD, machine learning, clonal hematopoiesis, cancer diagnostics, mutation characterization, precision oncology, molecular tumor board

The research underscores the crucial function of non-coding RNAs in gene regulation, especially in the context of cancer development. Unlike conventional protein-coding genes, non-coding RNAs do not translate into proteins but play vital roles in regulating gene expression at transcriptional and post-transcriptional levels. The manipulation of such molecules within the microenvironment of leukemias can engender profound changes in tumor behavior and therapeutic response.

EVs emerge as crucial carriers of these non-coding RNAs, providing a vehicle through which cells communicate and modulate their phenotypic characteristics. The vesicles are shed from various cell types, including tumor cells, and can be detected in bodily fluids such as blood and urine. This makes them tantalizing candidates for liquid biopsy applications, offering a non-invasive method for cancer detection and monitoring, with implications for patient management.

The authors reviewed numerous studies that investigated the content of EVs derived from leukemic cells. It has been observed that these vesicles can encapsulate various RNA species, including microRNAs and long non-coding RNAs, which can influence the behavior of both the tumor and surrounding stromal cells. For instance, specific microRNAs released from leukemic cells have been shown to foster a tumor-promoting microenvironment by affecting immune cell functions and enhancing angiogenesis, thereby facilitating tumor progression.

In pre-leukemic syndromes, the role of extracellular vesicle-derived ncRNAs might be critical in the early stages of disease progression. The evidence suggests that these molecules can serve as early biomarkers for predicting the transition from pre-leukemic conditions to full-blown leukemia. By understanding the ncRNA profiles found within EVs, researchers hope to identify potential therapeutic targets or even therapeutic agents that could ameliorate disease severity or progression.

One of the most promising aspects of this research is the therapeutic potential of targeting EVs themselves. Since these vesicles can mediate the delivery of anti-cancer agents or RNA-based therapeutics, manipulating their release or content might represent a novel approach to treating leukemias and their precursors. Innovative techniques such as RNA interference and CRISPR-based gene editing could be employed to modify the molecular content of EVs, which may enhance their efficacy as therapeutic vehicles.

Moreover, the potential to exploit these vesicles for both diagnostic and therapeutic approaches underscores the necessity for further research in this domain. It is imperative to expand our understanding of the biogenesis, secretion, and uptake pathways of EVs, as well as their interaction with various cell types within the hematological environment. Such knowledge will be essential for harnessing the full potential of EVs in clinical applications.

The review also highlights the need for standardized methodologies for isolating and characterizing extracellular vesicles to enable comparability among studies. Currently, the field faces challenges related to the heterogeneity of EV populations, which might complicate the interpretation of findings across different research efforts. Establishing universal standards will facilitate a clearer understanding of EV dynamics in leukemia and enhance collaborative efforts in this rapidly evolving field.

As the body of evidence supporting the role of extracellular vesicles in cancer biology grows, the medical community is urged to consider their therapeutic implications. The findings discussed by Seddighi et al. could inspire novel strategies in the combat against leukemia. By focusing on the ncRNA content of EVs, there is potential to uncover novel biomarkers for early intervention or innovative treatment modalities.

In conclusion, the comprehensive review by Seddighi and colleagues positions extracellular vesicle-derived non-coding RNAs as a promising frontier in leukemia research. The findings advocate for more robust investigations to explore the biological underpinnings that govern these systems. The hope is that, with further elucidation of these complex interactions, clinical applications rooted in the manipulation of EVs can be realized, heralding a new age in the management of leukemias and related disorders.

This systematic review not only consolidates current knowledge but also lays a foundation for future experimental designs and clinical trials targeting the intricacies of extracellular vesicle biology in leukemia. It calls for increased collaboration across disciplines to harness the potential of these tiny but powerful molecular messengers for significant advancements in treatment strategies.

Subject of Research: The role of extracellular vesicle-derived non-coding RNAs in leukemias and pre-leukemic syndromes.

Article Title: Extracellular vesicles-derived non-coding RNA in leukemias and pre-leukemic syndromes: a systematic review.

Article References:

Seddighi, N., Najafpour, M., Riyahi, M. et al. Extracellular vesicles-derived non-coding RNA in leukemias and pre-leukemic syndromes: a systematic review.
J Cancer Res Clin Oncol 152, 20 (2026). https://doi.org/10.1007/s00432-025-06385-6

Image Credits: AI Generated

DOI: https://doi.org/10.1007/s00432-025-06385-6

Keywords: Non-coding RNA, extracellular vesicles, leukemia, biomarkers, cancer therapy, intercellular communication.

Cell-free RNA has emerged as a promising biomarker due to its ability to reflect dynamic gene expression changes from various tissues. However, traditional approaches to cfRNA profiling have been hindered by low abundance, fragmentation, and contamination issues, particularly from platelets, which dilute the accuracy of measurements. The need for a refined, highly sensitive approach has been critical to harnessing cfRNA’s full clinical utility.

The team behind RARE-seq addressed these barriers by combining random priming with affinity capture to enrich cfRNA fragments before sequencing. This method significantly improves the recovery of low-copy transcripts, allowing for interrogation of gene expression patterns that were previously obscured by noise or overshadowed by background signals. The clever integration of affinity capture facilitates selective enrichment, ensuring that tumor-derived RNA can be reliably detected even at trace levels.

A notable hurdle in cfRNA research has been the confounding effect of platelet contamination, since platelets release RNA that can mask signals from diseased tissue. By developing an optimized protocol that minimizes platelet-derived interference, RARE-seq effectively isolates true circulating cfRNA signatures, thereby enhancing diagnostic precision. This breakthrough analytic refinement marks a pivotal advance over conventional whole-transcriptome RNA sequencing techniques.

Analytical validation demonstrated RARE-seq’s impressive sensitivity, achieving a limit of detection as low as 0.05% for tumor-derived cfRNA fragments. Compared directly to standard RNA-seq, the technique offered a staggering approximate 50-fold increase in sensitivity. This remarkable performance positions RARE-seq as a new gold standard for cfRNA analysis in both research and clinical contexts.

To illustrate clinical applicability, researchers applied RARE-seq to plasma samples from 369 individuals, encompassing patients with various stages of cancer alongside controls. In cases of non-small-cell lung cancer (NSCLC), the ability to detect tumor-specific expression signatures improved with disease progression—rising from 30% detection at stage I to an impressive 83% sensitivity at stage IV while maintaining 95% specificity. Such sensitivity surpasses that of standard circulating tumor DNA (ctDNA) assays, underscoring cfRNA’s emerging prominence as a complementary liquid biopsy analyte.

Beyond mere detection, RARE-seq effectively identified resistance mechanisms in patients undergoing targeted therapy. In EGFR-mutant NSCLC patients who developed resistance to tyrosine kinase inhibitors, the method uncovered both histological transformation and mutation-based resistance mutations. This dual detection capability highlights the potential of cfRNA monitoring not only for diagnosis but also for real-time therapeutic guidance and disease management.

The versatility of RARE-seq extends past oncology. The researchers demonstrated the technique’s capacity to pinpoint tissue of origin and to discriminate between malignant and benign pulmonary conditions, opening avenues for broader diagnostic utility. Additionally, RARE-seq was utilized to track immune responses following mRNA vaccination, offering insights into vaccine efficacy and host response dynamics at a molecular level.

Technically, RARE-seq leverages a sophisticated balance of molecular biology strategies. Random priming permits amplification of fragmented RNAs irrespective of sequence bias, while affinity capture enriches relevant cfRNA fragments by targeting unique biochemical features. This two-pronged approach dramatically increases yield and fidelity, ensuring that even minute amounts of tumor-specific RNA are amplified above background noise.

The impact of this ultrasensitive cfRNA analysis technique resonates beyond oncology, foreshadowing transformative applications in infectious disease, immunology, and personalized medicine. Real-time monitoring of gene expression shifts could enable clinicians to detect disease flare-ups, therapeutic resistance, or vaccination responses with unprecedented accuracy and timeliness.

As researchers continue to refine RARE-seq’s analytical pipeline and validate its utility across diverse patient populations and disease states, this method stands as a testament to the power of integrating molecular innovation with clinical insight. By overcoming longstanding technical limitations and delivering robust cfRNA profiles from plasma, RARE-seq sets a new standard for liquid biopsy technologies.

In an era where precision medicine continually pushes boundaries, the advent of RARE-seq represents a monumental stride towards truly non-invasive, comprehensive molecular diagnostics. This technology holds promise to revolutionize early detection, treatment monitoring, and biomarker discovery across a spectrum of diseases, ultimately improving patient outcomes through tailored interventions.

The unveiling of RARE-seq illustrates how innovative approaches to RNA biology can redefine translational medicine’s toolkit. Its heightened sensitivity, detection breadth, and adaptability position it as a transformative assay for future clinical trials, routine diagnostics, and personalized therapeutic strategies, underscoring a bold new chapter in biomarker research.

With its impressive ability to overcome crucial sensitivity and specificity barriers, RARE-seq may soon become indispensable in clinical practice and research, offering a powerful window into the elusive landscape of circulating RNA. As this technology gains traction, it promises to bridge critical gaps in our understanding of disease biology and therapeutic response, shining new light on the path toward individualized healthcare.

Subject of Research: Detection and analysis of cell-free RNA (cfRNA) for non-invasive gene expression profiling and disease monitoring.

Article Title: An Ultrasensitive Method for Detection of Cell-Free RNA

Article References:
Nesselbush, M.C., Luca, B.A., Jeon, YJ. et al. An ultrasensitive method for detection of cell-free RNA. Nature (2025). https://doi.org/10.1038/s41586-025-08834-1

Image Credits: AI Generated

At the heart of this ambitious program is the analysis of circulating tumor DNA (ctDNA), a novel tool that captures genetic material shed by cancer cells into the bloodstream. This approach offers a promising alternative to traditional tissue biopsies, providing a less invasive mechanism for monitoring tumor evolution. By examining ctDNA, the research team aims to unveil a more dynamic understanding of how genetic mutations arise, persist, and change throughout the cancer journey in young patients.

Led by Professor Louis Chesler from The Institute of Cancer Research, London, the SMPaeds1 initiative is noteworthy for its scale and scope. Supporting figures, such as Dr. Sally George, have played pivotal roles in advancing the methodologies employed. Their primary objective has been to illuminate the efficacy of ctDNA analysis, revealing its potential to detect additional mutations not identifiable through standard biopsy procedures. This unprecedented study positions itself as the most extensive to date, providing critical insights into matched ctDNA and tissue sequencing.

The results from the first phase of SMPaeds1, completed in October 2023, have opened new avenues in understanding pediatric cancers. Researchers demonstrated that ctDNA can reveal additional DNA mutations, presenting novel avenues for medical intervention. With these findings creating a foundation for future exploration, the study highlights the necessity of transitioning ctDNA from a research setting to clinical practice. Settling on clinical applicability could spell a new era in the treatment of pediatric cancer, where monitoring becomes seamless and minimally invasive.

As researchers probe deeper into the project’s data, they have begun to uncover specific DNA mutations that become enriched during relapse. By pinpointing these mutations, researchers can refine their focus, seeking to understand the mechanisms behind their proliferation and the implications for therapeutic approaches. Knowledge of these mutations assists in honing future research efforts, leading toward effective therapies that can specifically target the captivated mutations and improve patient outcomes.

The second phase, SMPaeds2, currently in progress, aims to build on the findings of the first phase. This next chapter seeks to develop an array of innovative tests to advance the understanding of blood cancers and solid tumors in pediatric patients. These tumors, which include difficult-to-access cancers affecting the brain, muscle, and bone, present unique challenges in diagnosis and treatment. Aligning innovative research efforts with a clearer comprehension of tumor biology could lead to breakthroughs in treatment regimens.

Amar Naher, CEO of Children with Cancer UK, articulated the organization’s commitment to advancing pediatric cancer research, emphasizing its mission to ensure that every child diagnosed with cancer has the opportunity to survive. By funding impactful research initiatives like SMPaeds, they aim to create a sustainable impact, paving the way for tailored treatments and less invasive monitoring protocols. This sentiment is echoed by Dr. Laura Danielson, the children’s and young people’s research lead at Cancer Research UK, who underscores the importance of evolving treatment landscapes through evidence-based findings.

The unique proposition of using ctDNA analysis extends beyond mere tracking; it delves into understanding the evolution of tumors and the therapeutic responses driving them. Investigating the molecular characteristics of cancers provides insights into why certain cases relapse or respond poorly to established treatments. Thus, the underlying goal remains to provide tailored therapies that align better with the genetic profiles of individual tumors, enhancing overall treatment efficacy.

As this research evolves, the collaborative efforts among researchers, healthcare professionals, and funding bodies will be critical to facilitating a smoother transition from laboratory findings to clinical practice. Enabling ctDNA tests to become clinical staples represents a substantial leap forward in the relentless fight against pediatric cancer. By combining advanced genomic technologies with clinical acumen, researchers are poised to address fundamental questions that challenge current treatment paradigms.

The implications of this research extend far beyond the immediate study. By unraveling the intricacies of pediatric cancers, researchers equip clinicians with tools and knowledge to face the dynamic nature of these diseases. Personalized treatment based on genetic profiling may become a standard approach, opening doors to novel therapeutic strategies and ensuring that young patients receive care that aligns with their specific needs.

Ultimately, the SMPaeds programs signify a commitment to integrating cutting-edge research with clinical excellence. By exploring the genetic underpinnings of pediatric cancers through ctDNA, researchers are fostering a culture of innovation and collaboration in oncology. This initiative not only raises hope for improved survival rates but also enhances the quality of life for young patients navigating the complex landscape of cancer treatment.

In conclusion, as the landscape of pediatric cancer treatment transforms through technologically advanced methodologies, initiatives like SMPaeds1 and SMPaeds2 serve as powerful reminders of how scientific innovation and collaboration can culminate in improved health outcomes for future generations. The commitment to minimizing the invasiveness and toxicity of treatments remains crucial, and with ongoing efforts, a brighter future for pediatric cancer patients is emerging, built on an understanding of their unique genetic challenges.

Subject of Research: Children and young people with cancer
Article Title: Stratified Medicine Pediatrics: Cell-Free DNA and Serial Tumor Sequencing Identifies Subtype-Specific Cancer Evolution and Epigenetic States
News Publication Date: 4-Feb-2025
Web References: https://aacrjournals.org/cancerdiscovery/article/doi/10.1158/2159-8290.CD-24-0916/751390/Stratified-Medicine-Pediatrics-Cell-Free-DNA-and
References: 10.1158/2159-8290.CD-24-0916
Image Credits: Cancer Discovery

Keywords: Cancer research, Children, Cancer treatments, Clinical research, Genetic testing